We agree that from a clinical perspective, standardization of a single, universally adopted, evidence-supported definition of a hypopnea event is an important goal. Many of the variations in the apnea-hypopnea index (AHI) that arise from different hypopnea definitions are, in effect, rescaled metrics of OSA disease severity. For example, in a comparison of recommended (AHI_{Rec}) and alternative (AHI_{Alt}) hypopnea definitions proposed by the American Academy of Sleep Medicine in 2007 (2), Ruehlman and colleagues (3) found that although the more liberal AHI_{Alt} definition produced ~80% higher mean AHIs, the correlation between AHI_{Rec} and AHI_{Alt} was high (0.93). Similarly, when Dean and colleagues (4) compared AHIs that (all else being equal) varied with the desaturation cutoff point (4% vs. 3%) and according to whether or not arousals were incorporated into the hypopnea definition, they also found that although the mean values varied substantially, the AHIs were highly correlated (generally >0.9). This suggests that for many patients, AHIs that use various hypopnea definitions contain similar information presented on different scales. Given this, it is indeed bizarre that the same cutoff points (e.g., 5, 15, or 30 events/h) should be used to define OSA severity categories whatever the hypopnea definition. Thus, for OSA classification in a clinical context, we agree that either a single standardized definition of hypopnea is required or different absolute cutoff points for OSA classification should be used for varying hypopnea definitions, with the former being the more parsimonious approach.

From a research perspective, however, we believe standardization of a single hypopnea definition would be needlessly limiting, given the current state of knowledge. Even though AHIs using different hypopnea definitions are highly correlated, they are not perfectly so. Thus, it may be that some definitions are more predictive of some outcomes. For example, Dean and colleagues found that an AHI definition that classified hypopneas by an oxygen desaturation of at least 4% (without considering arousals) was most consistently predictive of systolic blood pressure (4). However, it may be that definitions that incorporate arousals or lesser desaturations are better predictors of, say, long-term cognitive decline. Thus, in a research context, the scoring of polysomnograms in a manner that allows multiple definitions of breathing events to be flexibly generated is of substantial value. We hope that the next 25 years will bring nonproprietary computer algorithms for polysomnography interpretation that can rapidly and ever more accurately and reliably generate multiple characterizations of OSA to permit further exploration of important unanswered questions. ■

Author disclosures are available with the text of this letter at www.atsjournals.org.

Paul E. Peppard, Ph.D.
Erika W. Hagen, Ph.D.
University of Wisconsin-Madison
Madison, Wisconsin

References

1. Peppard PE, Hagen EW. The last 25 years of obstructive sleep apnea epidemiology—and the next 25? *Am J Respir Crit Care Med* 2018; 197:310–312.
2. Iber C, Ancoli-Israel S, Chesson A, Quan S. The AASM manual for the scoring of sleep and associated events: rules, terminology and technical specifications, 1st ed. Westchester, IL: American Academy of Sleep Medicine; 2007.
3. Ruehlman WR, Rochford PD, O'Donoghue FJ, Pierce RJ, Singh P, Thornton AT. The new AASM criteria for scoring hypopneas: impact on the apnea hypopnea index. *Sleep* 2009;32:150–157.
4. Dean DA, Wang R, Jacobs DR Jr, Duprez D, Punjabi NM, Zee PC, et al. A systematic assessment of the association of polysomnographic indices with blood pressure: the Multi-Ethnic Study of Atherosclerosis (MESA). *Sleep (Basel)* 2015;38:587–596.

Copyright © 2018 by the American Thoracic Society

Early Chronic Obstructive Pulmonary Disease or Early Detection of Mild Disease?

To the Editor:

The Perspective article by Martinez and colleagues on differentiating early chronic obstructive pulmonary disease (COPD) from mild disease is an excellent and timely discourse on this important topic (1). Mild and early airflow obstruction are frequently conflated by both clinicians and researchers. Mild disease, when observed, is hard to differentiate from early disease, and the only differentiator is temporal information. The authors propose a number of criteria to attempt differentiation of early and mild disease. Although these suggestions are practical, there are some issues with adapting the “required” criteria for clinical or research purposes. The recommendation that persons younger than 50 years of age should be considered to have early disease does not have a temporal component and does not take into consideration that a majority of smokers start smoking in their teens and hence would have already accumulated a substantial number of pack-years of smoking burden by the time they are in their forties. We recently showed that the duration of smoking is more strongly associated with measures of COPD than the composite index of pack-years (2). It is easy to ascertain the onset of smoking, and so a temporal component can be easily included by terming those with airflow obstruction within a conservative 10 years of smoking onset as having early COPD. For non-smoking-related COPD, temporality is harder to establish, but a lower age threshold may help.

Furthermore, a few other suggestions need clarification. First, the authors recommend using post-bronchodilator values for the lower limit of normal (LLN). Unfortunately, available LLN values are prebronchodilator. This is not a trivial issue; Tilert and colleagues showed that using post-bronchodilator fixed ratio less than 0.70 and prebronchodilator ratio less than LLN provide similar population estimates of airflow obstruction, whereas applying prebronchodilator criteria to post-bronchodilator tests results in prevalence estimates that are two-thirds of those obtained using prebronchodilator tests (3). Thus, post-bronchodilator LLN is likely to be more specific, but this may result in missing early cases of airflow obstruction for which sensitivity may be more important. Second, computed tomography can identify alteration in the lung parenchyma and airways before detection of airflow obstruction, but most smokers are likely to have some structural changes, and

Supported by NIH grant K23HL133438.

Originally Published in Press as DOI: 10.1164/rccm.201802-0257LE on April 13, 2018

more research is needed to establish thresholds for significant disease (4, 5). Finally, combining modes of diagnosis that are cross-sectional snapshots with those that measure longitudinal changes may introduce considerable heterogeneity to case detection. Using data from electronic medical records where available is a good suggestion, but more clarity is needed as to how long the decline of 60 ml/yr in FEV₁ needs to be sustained. For example, an acute respiratory illness may cause a drop in FEV₁, and the subsequent age-related decline may result in an absolute drop in FEV₁ over time, but this may not mean the decline is continuing. The authors describe a pertinent problem of detecting mild disease late in life that may remain mild and not progress. This Perspective is an excellent start, but we need to make sure we are detecting early disease and not just detecting mild disease at an earlier chronological age. ■

Author disclosures are available with the text of this letter at www.atsjournals.org.

Surya P. Bhatt, M.D.
University of Alabama at Birmingham
Birmingham, Alabama

ORCID ID: 0000-0002-8418-4497 (S.P.B.).

References

1. Martinez FJ, Han MK, Allinson JP, Barr RG, Boucher RC, Calverley PMA, *et al.* At the root: defining and halting progression of early chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 2018;197: 1540–1551.
2. Bhatt SP, Kim YI, Harrington KF, Hokanson JE, Lutz SM, Cho MH, *et al.*; COPDGene Investigators. Smoking duration alone provides stronger risk estimates of chronic obstructive pulmonary disease than pack-years. *Thorax* 2018;73:414–421.
3. Tilert T, Dillon C, Paulose-Ram R, Hnizdo E, Doney B. Estimating the U.S. prevalence of chronic obstructive pulmonary disease using pre- and post-bronchodilator spirometry: the National Health and Nutrition Examination Survey (NHANES) 2007–2010. *Respir Res* 2013; 14:103.
4. Bhatt SP, Soler X, Wang X, Murray S, Anzueto AR, Beaty TH, *et al.*; COPDGene Investigators. Association between functional small airway disease and fev1 decline in chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 2016;194: 178–184.
5. Woodruff PG, Barr RG, Bleecker E, Christenson SA, Couper D, Curtis JL, *et al.*; SPIROMICS Research Group. Clinical significance of symptoms in smokers with preserved pulmonary function. *N Engl J Med* 2016; 374:1811–1821.

Copyright © 2018 by the American Thoracic Society